Pharmaceutical applications of cyanobacteria—A review

Vijayakumar, Sekar; Menakha, Muniraj

doi:10.1016/j.jacme.2015.02.004

Cited by 172 publications

(114 citation statements)

References 94 publications

Supporting

Mentioning

105

Contrasting

Unclassified

Order By: Relevance

“…These oxygenic photosynthetic prokaryotes, which form a single taxonomic and phylogenetic group, produce a broad range of bioactive compounds including ones that show anti-microbial, anti-protozoal and anti-inflammatory activity (Micallef et al 2015;Vijayakumar and Menakha 2015). Endolithic (rock-inhabiting) cyanobacteria dominated by Chroococcidiopsis species were first reported from the Negev Desert (Potts and Friedmann 1981), but are now known to be common in desert biomes given their remarkable ability to cope with extreme aridity and solar radiation (Lacap-Bugler et al 2017).…”

Section: Cyanobacteriamentioning

confidence: 99%

“…Especially gifted actinobacteria that have moderate or large genomes (~5Á0-7Á9 and >8Á0 MB respectively) harbour many NP-BGCs (20-19 and >30 respectively) (Baltz 2017(Baltz , 2019Nouioui et al 2019) are at the premium in the search for new chemical leads using state-of-art-technologies, such as genome mining (Harvey et al 2015;Goodfellow et al 2018). Other micro-organisms with large genomes laden with NP-BGCs include cyanobacteria (Vijayakumar and Menakha 2015), ktedonobacteria (Zheng et al 2019), myxobacteria (Hoffmann et al 2018) and fungi (Keller et al 2005). Indeed, members of all of these taxa have been highlighted as potential candidates for drug discovery programmes (Dixit and Suseela 2013;Micallef et al 2015;Baltz 2019;Keller 2019).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Extreme environments: microbiology leading to specialized metabolites

et al. 2019

View full text Add to dashboard Cite

Summary The prevalence of multidrug‐resistant microbial pathogens due to the continued misuse and overuse of antibiotics in agriculture and medicine is raising the prospect of a return to the preantibiotic days of medicine at the time of diminishing numbers of drug leads. The good news is that an increased understanding of the nature and extent of microbial diversity in natural habitats coupled with the application of new technologies in microbiology and chemistry is opening up new strategies in the search for new specialized products with therapeutic properties. This review explores the premise that harsh environmental conditions in extreme biomes, notably in deserts, permafrost soils and deep‐sea sediments select for micro‐organisms, especially actinobacteria, cyanobacteria and fungi, with the potential to synthesize new druggable molecules. There is evidence over the past decade that micro‐organisms adapted to life in extreme habitats are a rich source of new specialized metabolites. Extreme habitats by their very nature tend to be fragile hence there is a need to conserve those known to be hot‐spots of novel gifted micro‐organisms needed to drive drug discovery campaigns and innovative biotechnology. This review also provides an overview of microbial‐derived molecules and their biological activities focusing on the period from 2010 until 2018, over this time 186 novel structures were isolated from 129 representatives of microbial taxa recovered from extreme habitats.

show abstract

Section: Cyanobacteriamentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Extreme environments: microbiology leading to specialized metabolites

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Biotechnology oriented research with cyanobacteria ranges from the production of low-cost material like bulk chemicals or biofuels (1) to high-value compounds like pharmaceutics (2). Advancements in cyanobacterial biotechnology are based on continued optimization of photobioreactors, the introduction and improvement of metabolic pathways by recombinant DNA technology, and the search for suitable organisms (3, 4).…”

Section: Introductionmentioning

confidence: 99%

Natural transformation of the filamentous cyanobacterium Phormidium lacuna

Nies

Mielke

Pochert

et al. 2019

Preprint

View full text Add to dashboard Cite

9Research for biotechnological applications of cyanobacteria focuses on synthetic pathways and 10 bioreactor design, while little effort is devoted to introduce new, promising organisms in the field. 11Applications are most often based on recombinant work, and the establishment of transformation 12 can be a risky, time-consuming procedure. In this work we demonstrate the natural transformation 13 of the filamentous cyanobacterium Phormidium lacuna and insertion of a selection marker into the 14 genome by homologous integration. This is the first example for natural transformation of a member 15 of the order Oscillatoriales. We found that Phormidium lacuna is polyploid, each cell has about 20-16 100 chromosomes. Transformed filaments were resistant against up to 15 mg/ml of kanamycin, and 17 the high resistance feature allowed for rapid segregation into all chromosomes. Formerly, natural 18 transformation in cyanobacteria has been considered a rare and exclusive feature of a few unicellular 19 species. Our finding suggests that natural competence is more distributed among cyanobacteria than 20 previously thought. This is supported by bioinformatic analyses which show that all protein factors 21 for natural transformation are present in the majority of the analyzed cyanobacteria. 22

show abstract

“…The phylum cyanobacteria has been explored for a long time due to its high biotechnological potential, mainly because of bioactive compound production [1,2]. In this regard, some lectins produced by algae and cyanobacteria are notable for their high antiviral activity against HIV, severe acute respiratory syndrome (SARS) coronavirus and Zaire Ebola virus [3].…”

Section: Introductionmentioning

confidence: 99%

In silico analysis of the cyanobacterial lectin scytovirin: new insights into binding properties

et al. 2017

View full text Add to dashboard Cite

Scytovirin is a lectin isolated from the cyanobacterium Scytonema varium that has shown activity against HIV, SARS coronavirus and Zaire Ebola virus. Its 95 amino acids are divided into two structural domains (SD), the first spanning amino acids 1-48 (SD1) and the second 49-95 (SD2). Interestingly, the domains are nearly identical but differ in their affinities for carbohydrates. With the aim of enhancing understanding of the binding properties of scytovirin, we performed molecular dynamics (MD) simulations of scytovirin complexed with Man4. We set up three systems: (i) Man4 bound to both domains (SD1 + SD2) using the full-length protein; (ii) Man4 bound to an incomplete protein, containing only SD1 and (iii) Man4 bound to an incomplete protein containing only SD2. Contrary to other reports, binding free energy results suggest that Man4 can bind simultaneously to SD1 and SD2 binding regions, but SD1 individually has the best values of energy and the best affinity for Man4. Decomposition of the binding free energy showed that the residues that interact with Man4 were different in the three systems, suggesting that the binding mechanism of Man4 varies between full-length protein, SD1 and SD2. The results presented here may help to formulate strategies to use scytovirin and promote mutagenesis studies to improve the antiviral activity of scytovirin.

show abstract

Pharmaceutical applications of cyanobacteria—A review

Cited by 172 publications

References 94 publications

Extreme environments: microbiology leading to specialized metabolites

Extreme environments: microbiology leading to specialized metabolites

Natural transformation of the filamentous cyanobacterium Phormidium lacuna

In silico analysis of the cyanobacterial lectin scytovirin: new insights into binding properties

Contact Info

Product

Resources

About